Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
Overview | Financials
Company Name | Rhythm Pharmaceuticals, Inc. |
Symbol | RYTM |
Currency | USD |
Price | 53.66 |
Market Cap | 3,297,787,986 |
Dividend Yield | 0% |
52-week-range | 35.17 - 68.58 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. David P. Meeker M.D. |
Website | https://www.rhythmtx.com |
An error occurred while fetching data.
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD